SMTL ID : 7oy5.1

Crystal structure of GSK3Beta in complex with ARN25068

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.57 Å

Oligo State

homo-dimer

Ligands

2 x 39I: ~{N}4-(3-cyclopropyl-1~{H}-pyrazol-5-yl)-~{N}2-(phenylmethyl)thieno[3,2-d]pyrimidine-2,4-diamine(Non-covalent)

39I.1: 15 residues within 4Å: Chain A: I.28, V.36, A.49, L.98, D.99, Y.100, V.101, P.102, E.103, R.107, Q.151, N.152, L.154, C.165 Ligands: CL.2 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:V.36, A:A.49, A:L.98, A:L.154 Hydrogen bonds: A:I.28, A:V.101, A:V.101, A:V.101 39I.6: 14 residues within 4Å: Chain B: I.28, A.49, L.98, D.99, Y.100, V.101, P.102, E.103, R.107, Q.151, N.152, L.154, C.165 Ligands: CL.7 5 PLIP interactions: 5 interactions with chain B Hydrophobic interactions: B:A.49, B:L.98 Hydrogen bonds: B:V.101, B:V.101, B:V.101

6 x CL: CHLORIDE ION(Non-functional Binders)

CL.2: 3 residues within 4Å: Chain A: K.51, D.166 Ligands: 39I.1 Ligand excluded by PLIP CL.3: 2 residues within 4Å: Chain A: T.104, Q.151 Ligand excluded by PLIP CL.4: 2 residues within 4Å: Chain A: P.346, H.347 Ligand excluded by PLIP CL.5: 1 residues within 4Å: Chain A: Y.127 Ligand excluded by PLIP CL.7: 3 residues within 4Å: Chain B: K.51, D.166 Ligands: 39I.6 Ligand excluded by PLIP CL.8: 2 residues within 4Å: Chain B: T.104, Q.151 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Demuro, S. et al., ARN25068, a versatile starting point towards triple GSK-3 beta /FYN/DYRK1A inhibitors to tackle tau-related neurological disorders. Eur.J.Med.Chem. (2022)

Release Date

2022-03-02

Peptides

Glycogen synthase kinase-3 beta: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Glycogen synthase kinase-3 beta

Related Entries With Identical Sequence